Thermal behavior of novel non-sonicated arsonolipid-containing liposomes

Koutsopoulos, Sotirios; Fatouros, Dimitrios G.; Ioannou, Panayiotis V.; Antimisiaris, Sophia G.

doi:10.1016/j.bpc.2006.01.006

Cited by 6 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arsonoliposomes are nanosized liposomes constituted from arsonolipids, which are analogs of phosphonolipids where arsenic replaces the phosphorus in the lipid polar head group [47] . This type of nanoparticles is designed to combine the anti-cancer properties of arsenic with the enhanced efficacy and reduced toxicity of liposomes.…”

Section: Encapsulation Of Ato As a Single Agent Or Co-encapsulated Wimentioning

confidence: 99%

Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers

Akhtar¹,

Wang²,

Ghali³

et al. 2017

J Biomed Res

View full text Add to dashboard Cite

Since arsenic trioxide was first approved as the front line therapy for acute promyelocytic leukemia 25 years ago, its anti-cancer properties for various malignancies have been under intense investigation. However, the clinical successes of arsenic trioxide in treating hematological cancers have not been translated to solid cancers. This is due to arsenic's rapid clearance by the body's immune system before reaching the tumor site. Several attempts have henceforth been made to increase its bioavailability toward solid cancers without increasing its dosage albeit without much success. This review summarizes the past and current utilization of arsenic trioxide in the medical field with primary focus on the implementation of nanotechnology for arsenic trioxide delivery to solid cancer cells. Different approaches that have been employed to increase arsenic's efficacy, specificity and bioavailability to solid cancer cells were evaluated and compared. The potential of combining different approaches or tailoring delivery vehicles to target specific types of solid cancers according to individual cancer characteristics and arsenic chemistry is proposed and discussed.

show abstract

Section: Encapsulation Of Ato As a Single Agent Or Co-encapsulated Wimentioning

confidence: 99%